Detalles de la búsqueda
1.
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
BMC Cancer
; 24(1): 176, 2024 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38317094
2.
The Effects of One-Point Mutation on the New Delhi Metallo Beta-Lactamase-1 Resistance toward Carbapenem Antibiotics and ß-Lactamase Inhibitors: An In Silico Systematic Approach.
Int J Mol Sci
; 23(24)2022 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36555726
3.
Structure-Based Discovery of ABCG2 Inhibitors: A Homology Protein-Based Pharmacophore Modeling and Molecular Docking Approach.
Molecules
; 26(11)2021 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34071039
4.
Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Ther Adv Med Oncol
; 16: 17588359241242972, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38736554
5.
Targeting Olokizumab-Interleukin 6 interaction interface to discover novel IL-6 inhibitors.
J Biomol Struct Dyn
; 41(23): 14003-14015, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995131
6.
Chalcone Derivatives as Potential Inhibitors of P-Glycoprotein and NorA: An In Silico and In Vitro Study.
Biomed Res Int
; 2022: 9982453, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35378788
7.
Exploration of chalcones as 3-chymotrypsin-like protease (3CLpro) inhibitors of SARS-CoV-2 using computational approaches.
Struct Chem
; 33(5): 1707-1725, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35811783
Resultados
1 -
7
de 7
1
Próxima >
>>